Show summary Hide summary
The Food and Drug Administration has cleared a new once-daily HIV pill from Gilead, a medication the company says could simplify treatment for people whose virus is suppressed but who cannot use existing one-pill regimens. The drug, sold as Bixlenvo, pairs two antiviral agents and is intended both for patients with complex treatment histories and for those seeking an alternative to their current therapy.
How the pill works
Bixlenvo combines bictegravir — the integrase inhibitor that underpins Gilead’s widely used Biktarvy — with lenacapavir, a capsid inhibitor that represents a newer class of HIV drugs. Gilead says this is the first single-tablet regimen approved for adults whose virus is suppressed but who cannot take existing one-pill options.
Ultra-thin women smoking cigarettes are making a comeback as a fashion trend
Windows Memory Diagnostic explained: what the test does and how to read results
The company estimated to CNBC that this group makes up roughly 5% or more of people living with HIV in the U.S. These patients often require multi-drug schedules because of prior drug resistance, side effects or interactions with other medicines.
Who may benefit
Gilead and its clinical team frame Bixlenvo as an option for two main groups: people on complicated, multi-pill regimens who could consolidate treatment, and people already doing well on a single-tablet therapy who want an alternative.
“It fulfills an unmet need, particularly for individuals who are on complex regimens who just would not otherwise consolidate down to something really meaningful for them and prescribers,” said Dr. Jared Baeten, Gilead’s head of clinical development and virology. He added that expanding choices helps patients find regimens that fit their preferences and lifestyles.
Clinical evidence and patient experience
The FDA decision was based on two Phase 3 studies that enrolled adults whose virus was already suppressed. One of those trials, ARTISTRY-1, specifically recruited people with long histories of treatment and documented drug resistance. Participants in ARTISTRY-1 had a median age of 60 and reported taking between two and 11 pills daily before switching to the single-tablet regimen.
In both trials, Bixlenvo maintained viral suppression at rates similar to participants’ prior regimens at 48 weeks. Reported side effects occurring in at least 2% of participants included headache, nausea and diarrhea, and no new safety signals emerged.
Timothy Cameron, a 64-year-old retired Seattle resident who took part in ARTISTRY-1, described a decades-long struggle with limited options and rising resistance after his diagnosis in the 1980s. He said switching to the once-daily pill was seamless: the drug kept his virus controlled without new side effects and reduced the number of medications he takes.
“It was just like throwing darts at a dartboard,” Cameron said of earlier treatment efforts that failed as resistance developed. He added that taking fewer medicines helps preserve future options: “It’s one less thing I’m putting in my body, and it preserves options if I need them.”
Price and access
Gilead reported a list price of $4,595 for a 30-day supply before discounts or rebates, noting that this level is comparable to other daily single-tablet HIV treatments. The company said people without insurance may qualify for free medication through its patient assistance program, and those with commercial plans may be eligible for co-pay support via a separate savings program.
Part of a larger strategy
Gilead describes Bixlenvo as one element of a broader effort to build treatment choices around lenacapavir that include daily pills, weekly oral options and long-acting injectables. “We’re going to build enough options that people can make the choice that’s going to work for them,” Baeten said, noting that some patients prefer the predictability of a daily pill while others may favor less frequent dosing.
